"We need financial sustainability of HIV and TB services and their further integration into the national health systems".

This report presents data on HIV and AIDS in 51 of 53 countries in the WHO European Region, and in the European Union and European Economic Area (EU/EEA).

Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single-tablet regimen (STR), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with ...

The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade. According to data published by ECDC, the number of confirmed ...

At its June meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection. Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is available here. [gview ...

Countries in Western and Southern Europe are well on their way to meeting the UNAIDS 90-90-90 targets, according to a study published in Clinical Infectious Diseases. Using data collected to the end of 2013, a survey of eleven countries shows that an estimated 84% of people ...

Hepatitis B and C virus infections are associated with a considerable burden of disease in Europe. ECDC undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C in the EU/EEA, and to update the existing ...

As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen Epclusa (; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of the International Liver Conference (ILC) 2017, ...

Harm Reduction International released a report, Harm reduction investment in the European Union: Current spending, challenges and successes ahead of the 25th Harm Reduction International Conference (HR17) taking place on 14 – 17 May 2017 in Montréal, Canada. [gview file="http://ecuo.org/mvdev/wp-content/uploads/sites/4/2017/05/HRWreportApril2017_web_1.pdf"] [gview file="http://ecuo.org/mvdev/wp-content/uploads/sites/4/2017/05/thepolicy2017_online_version.pdf"] Europe is the birthplace of harm ...

​The continuum of HIV care is a framework that enables countries to monitor the effectiveness of their HIV response - from diagnosis towards viral suppression (which means that the virus is no longer detectable in the blood). This report provides a snapshot of the status ...

Please read and share the letter signed by EATG, as Europe’s transnational HIV treatment and prevention advocacy group, and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs, requesting Gilead Sciences to make it possible for Truvada®, or for generic equivalents of ...

Abstract Background In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment goals for human immunodeficiency virus (HIV). The 90-90-90 target specifies that by 2020, 90% of individuals living with HIV will know their HIV status, 90% of people with diagnosed HIV infection will receive ...

Abstract Background UNAIDS has set a 90-90-90 target to curb the HIV epidemic by 2020, but methods used to assess whether countries have reached this target are not standardised, hindering comparisons. Methods Through a collaboration formed by the European Centre for Disease Prevention and Control (ECDC) with European HIV ...

Patent opposition aims to increase affordable access to hepatitis C drug sofosbuvir for millions Rome/Geneva, 27 March 2017 – The international medical humanitarian organisation Médecins Sans Frontières (MSF) has today filed a patent challenge on the hepatitis C drug sofosbuvir with the European Patent Office (EPO) ...

Copenhagen and Stockholm, 20 March 2017 New data released today by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe ahead of World TB Day show that new tuberculosis (TB) cases and deaths in the 53 countries of the ...

Summary Background Sex workers are disproportionately affected by HIV compared with the general population. Most studies of HIV risk among sex workers have focused on individual-level risk factors, with few studies assessing potential structural determinants of HIV risk. In this Article, we examine whether criminal laws around ...

The vast majority of people taking antiretroviral therapy (ART) in the UK have an accurate knowledge of their current viral load (VL) level, investigators report in HIV Medicine. Overall, 96% of people who told researchers their viral load was undetectable had a clinic-recorded viral load ...

LONDON (Thomson Reuters Foundation) - One in seven people with HIV in the Europe Union region is unaware they have the virus, seriously hampering efforts to meet a global 2030 deadline for eradicating the AIDS epidemic, a senior health expert said on Tuesday. The average estimated ...